Market Overview:
The global viral vector vaccines market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of infectious diseases, rising demand for novel vaccine technologies, and growing focus on research and development activities for new viral vector vaccines. Based on type, the global viral vector vaccines market can be segmented into adenovirus vectors, fowlpox virus vectors, attenuated yellow fever vectors, vaccinia virus vectors, and others. Adenovirus vectors are expected to account for the largest share of the global viral vector vaccines market in 2018 owing to their ability to express foreign genes efficiently and their wide use in clinical trials. Fowlpox virus is another major type of vector used in vaccine development owing its high immunogenicity and safety profile. Attenuated yellow fever viruses are also being increasingly used as vaccine vectors due to their ability induce long-term immunity against flaviviruses such as yellow fever virus (YFV) and dengue virus (DENV). Vaccinia viruses are also being increasingly used as vaccine vectors due to their large genome size that allows incorporation of multiple antigens into a single construct. Based on application, hospitals accounted for the largest share of the global viral vector vaccines market in 2017 owingto thier widespread usein diagnosisand treatmentof infectious diseases.
Product Definition:
A viral vector vaccine is a vaccine that uses a virus to carry and deliver the antigen or DNA of another pathogen into the cells of the vaccinated person. This allows for a high level of expression and presentation of the antigen on the surface of cells, which facilitates an immune response.
Adenovirus:
Adenovirus is a virus of the family Picornaviridae. There are more than 100 serotypes of adenovirus and they are generally found in animals and humans. The viruses can be segmented into two types based on their size: small-sized (40 to 50 nm) and large-sized (200 to 250 nm). Adenoviruses belong to the large group of non-segmented positive-stranded RNA viruses.
Fowlpox Virus:
Fowlpox virus (FPV) is the causative agent of fowlpox. It is a member of the Ortho-urol family. The disease was first described in 1783 and has been recorded as an endemic to almost all countries with human habitation, including Canada, Mexico, U.S., Australia, New Zealand and some European countries such as Italy and Spain.
Application Insights:
Based on application, the market is segmented into hospitals, clinics and other medical facilities. Hospitals are expected to dominate the application segment over the forecast period owing to increasing incidences of infectious diseases that are transmitted through contact with infected individuals. This has resulted in a significant increase in demand for viral vector vaccines at hospital-level settings.
The others segment includes pre-school institutions, boarding schools and colleges, daycare centers and orphanages etc., These organizations do not necessarily have access to advanced healthcare facilities but still need to be vaccinated against highly infectious diseases such as yellow fever virus or measles virus since they cannot be treated with antibiotics or antiviral drugs etc. Thus these establishments require a high dose of vaccine compared to that required for an individual patient due to large number of occupants in these places which results in higher production capacity needed for manufacturing viral vector vaccines at economical rates compared to that required by hospitals & clinics.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, increasing investment by these companies for development and commercialization of vaccines, and high prevalence of diseases such as Ebola Virus Disease (EVD), Middle East Respiratory Syndrome (MERS), H1N1 influenza among others. Moreover, growing focus on biodefense activities is also expected to drive demand over the forecast period.
The European region accounted for second-largest share in terms of revenue generation owing to early adoption and implementation of viral vector technology coupled with rising awareness about potential benefits associated with these therapies. Furthermore, increasing R&D investments by major players is further anticipated to propel growth during the forecast period. For instance; GlaxoSmithKline plc.
Growth Factors:
- Increasing incidence of infectious diseases: The increasing incidence of infectious diseases is one of the major growth drivers for the viral vector vaccines market. Infectious diseases are caused by pathogenic microorganisms such as viruses, bacteria, and parasites. These infections can cause a wide range of symptoms, depending on the type and severity of infection. The increasing incidence of infectious diseases due to changing lifestyles, growing population, and global travel is expected to drive the demand for viral vector vaccines in the coming years.
- Technological advancements in vaccine development: The technological advancements in vaccine development are another major growth driver for the viral vector vaccines market. With continuous research and development activities in this field, new and innovative vaccine technologies are being developed that can help improve disease prevention strategies worldwide. This is expected to boost demand for viral vector vaccines in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Viral Vector Vaccines Market Research Report
By Type
Adenovirus, Fowlpox Virus, Attenuated Yellow Fever, Vaccinia Virus Vectors, Others
By Application
Hospitals, Clinics, Others
By Companies
Advanced Bioscience Laboratories, Boehringer Ingelheim, Brammer Bio, Creative Biogene, GE Healthcare, Pfizer, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
128
Number of Tables & Figures
90
Customization Available
Yes, the report can be customized as per your need.
Global Viral Vector Vaccines Market Report Segments:
The global Viral Vector Vaccines market is segmented on the basis of:
Types
Adenovirus, Fowlpox Virus, Attenuated Yellow Fever, Vaccinia Virus Vectors, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Advanced Bioscience Laboratories
- Boehringer Ingelheim
- Brammer Bio
- Creative Biogene
- GE Healthcare
- Pfizer
- Sanofi
Highlights of The Viral Vector Vaccines Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Adenovirus
- Fowlpox Virus
- Attenuated Yellow Fever
- Vaccinia Virus Vectors
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Viral Vector Vaccines Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Viral vector vaccines are a type of vaccine that uses a virus to help the body build immunity. This type of vaccine is different from traditional vaccines, which use dead or weakened viruses to help the body develop immunity. Viral vector vaccines use live viruses that have been modified so they can't cause disease but still trigger an immune response in the body.
Some of the major players in the viral vector vaccines market are Advanced Bioscience Laboratories, Boehringer Ingelheim, Brammer Bio, Creative Biogene, GE Healthcare, Pfizer, Sanofi.
The viral vector vaccines market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Viral Vector Vaccines Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Viral Vector Vaccines Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Viral Vector Vaccines Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Viral Vector Vaccines Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Viral Vector Vaccines Market Size & Forecast, 2020-2028
4.5.1 Viral Vector Vaccines Market Size and Y-o-Y Growth
4.5.2 Viral Vector Vaccines Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Adenovirus
5.2.2 Fowlpox Virus
5.2.3 Attenuated Yellow Fever
5.2.4 Vaccinia Virus Vectors
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Viral Vector Vaccines Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Viral Vector Vaccines Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Adenovirus
9.6.2 Fowlpox Virus
9.6.3 Attenuated Yellow Fever
9.6.4 Vaccinia Virus Vectors
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Adenovirus
10.6.2 Fowlpox Virus
10.6.3 Attenuated Yellow Fever
10.6.4 Vaccinia Virus Vectors
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Adenovirus
11.6.2 Fowlpox Virus
11.6.3 Attenuated Yellow Fever
11.6.4 Vaccinia Virus Vectors
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Adenovirus
12.6.2 Fowlpox Virus
12.6.3 Attenuated Yellow Fever
12.6.4 Vaccinia Virus Vectors
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Adenovirus
13.6.2 Fowlpox Virus
13.6.3 Attenuated Yellow Fever
13.6.4 Vaccinia Virus Vectors
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Viral Vector Vaccines Market: Competitive Dashboard
14.2 Global Viral Vector Vaccines Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Advanced Bioscience Laboratories
14.3.2 Boehringer Ingelheim
14.3.3 Brammer Bio
14.3.4 Creative Biogene
14.3.5 GE Healthcare
14.3.6 Pfizer
14.3.7 Sanofi
